RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2041-4889
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer ; volume:11 ; number:10 ; day:29 ; month:10 ; year:2020 ; pages:1-18 ; date:10.2020
Cell death & disease ; 11, Heft 10 (29.10.2020), 1-18, 10.2020
- Creator
-
Khawaja, Hajrah
Campbell, Andrew
Roberts, Jamie Z.
Javadi, Arman
O’Reilly, Paul
McArt, Darragh
Allen, Wendy L.
Majkut, Joanna
Rehm, Markus
Bardelli, Alberto
Nicolantonio, Federica Di
Scott, Christopher J.
Kennedy, Richard
Vitale, Nicolas
Harrison, Timothy
Sansom, Owen J.
Longley, Daniel B.
Evergren, Emma
Schaeybroeck, Sandra Van
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41419-020-03131-3
- URN
-
urn:nbn:de:101:1-2020121313003210966689
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Khawaja, Hajrah
- Campbell, Andrew
- Roberts, Jamie Z.
- Javadi, Arman
- O’Reilly, Paul
- McArt, Darragh
- Allen, Wendy L.
- Majkut, Joanna
- Rehm, Markus
- Bardelli, Alberto
- Nicolantonio, Federica Di
- Scott, Christopher J.
- Kennedy, Richard
- Vitale, Nicolas
- Harrison, Timothy
- Sansom, Owen J.
- Longley, Daniel B.
- Evergren, Emma
- Schaeybroeck, Sandra Van
- SpringerLink (Online service)
Other Objects (12)
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
Current therapy of KRAS-mutant lung cancer
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
The RAB6 GTPase, a master regulator of post-Golgi trafficking pathways
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
Current therapy of KRAS-mutant lung cancer
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
The RAB6 GTPase, a master regulator of post-Golgi trafficking pathways
Targeting a defective DNA damage response in KRAS-mutant adenocarcinomas
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Target Mutant KRAS with Molecular Glue
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells
Current therapy of KRAS-mutant lung cancer
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
The RAB6 GTPase, a master regulator of post-Golgi trafficking pathways